Affluent Medical SA reported the imminent raising of nearly $14 million to fund development throughout 2023 of its implantable medical devices for treating urinary incontinence and heart valve pathology. Affluent, quoted on the Paris Euronext stock exchange since 2021, issued new shares accompanied by redeemable share warrants with shareholder preferential subscription rights being preserved.
Rhaeos Inc. scooped up $10.5 million in a series A financing round led by Steele Foundation for Hope, with participation from Creative Ventures and Lateral Capital. The funds will be used to support the hospital launch of its Flowsense wearable hydrocephalus shunt monitor.
Xeltis BV has completed a €32 million (US$34 million) series D2 round that will propel the clinical development of its electrospun polymer implants across several indications. The fully synthetic implants promise the best of both worlds, with the mechanical strength required to be fully functional from day one, and bioresorbable properties that cause gradual degradation as endogenous tissue regenerates to form a natural replacement.
Creo Medical Group plc is on its way to being cash flow breakeven and profitable following a successful fundraise, which will accelerate the rollout of its suite of electrosurgical products, CEO Craig Gulliford told BioWorld.
Previa Medical SA will begin clinical trials later this year of its artificial intelligence software designed for early detection of sepsis after it raised €2.1 million (US $2.2 million) in seed funds.
Hygea Medical Technology Co. Ltd. has completed a series D funding round to develop an integrated platform for interventional oncology procedures and expand globally.
RSS
